Catalog No.
Product Name
Application
Product Information
Citations
-
KRAS G12C Mutant Inhibitor
KRAS G12C-IN-70 is a selective inhibitor that targets the KRAS G12C mutant, effectively disrupting downstream signaling pathways such as RAF-MEK-ERK. This inhibition leads to a reduction in tumor cell proliferation, making KRAS G12C-IN-70 a valuable tool for research into tumors associated with the KRAS G12C mutation, including non-small cell lung cancer and colorectal cancer. Researchers investigating the therapeutic potential of targeting KRAS G12C will find this compound particularly useful. -
KRas Inhibitor
SS-3091 is a pan KRas inhibitor that targets the interaction interfaces of KRas, leading to the destabilization of the ARaf/KRas complex and modulation of downstream signaling pathways. This compound exhibits significant anticancer and antiproliferative effects against various KRas mutant forms, including G12D, G12C, G12V, and G12S, in a range of cancer cell lines. SS-3091 is valuable for research into KRas-mediated signaling and its implications in cancer biology. -
FTase Inhibitor
BIM-46068 is a selective inhibitor of human brain Farnesyltransferase (FTase) with an IC50 of 91.4 nM. This compound effectively inhibits Ras processing in MiaPaCa-2 cancer cells, making it a valuable tool for research on pancreatic cancer. Its ability to specifically target FTase positions BIM-46068 as an important reagent for exploring the molecular mechanisms underlying Ras signaling in cancer. -
KRAS G12C Inhibitor
KRAS Inhibitor-17 is a selective inhibitor targeting the KRAS G12C oncogenic mutation, exhibiting an IC50 of 3.37 µM. It effectively inhibits phosphorylated ERK (p-ERK) with IC50 values of 9.25 µM in MIA PaCA-2 cells and >33.3 µM in A549 cells. This compound holds promise for advancing research in pancreatic, colorectal, and lung cancers, contributing to the understanding of KRAS-driven tumorigenesis. -
Ras Binder
DCAI is a Ras protein binder that specifically inhibits Ras activation and nucleotide exchange facilitated by SOS. This compound is valuable for studying cancer associated with mutations in the Ras gene, providing insight into the molecular mechanisms underlying Ras-driven tumorigenesis. DCAI serves as an essential tool for researchers investigating targeted therapies for Ras-related cancers. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 45 is a selective inhibitor that targets the KRAS G12C mutation, which plays a crucial role in various cancers. This compound demonstrates significant biological activity by inhibiting the downstream signaling pathways associated with KRAS G12C, thereby inducing apoptosis in tumor cells harboring this mutation. It is a valuable tool for cancer research, particularly in studies focusing on personalized medicine and targeted therapies for KRAS G12C-positive tumors. -
KRAS Inhibitor
KRAS inhibitor-21 is a potent inhibitor targeting the KRAS G12C mutation with an IC50 value of less than 0.01 μM. This compound demonstrates significant biological activity in attenuating KRAS-mediated signaling pathways, making it a valuable tool for investigating mechanisms of oncogenic transformation. It is particularly useful in cancer research aimed at exploring therapeutic strategies for KRAS-driven malignancies. -
KRAS Inhibitor
KRAS inhibitor-34 is a selective inhibitor targeting the KRAS protein, exhibiting an IC50 of 6.4 nM. This compound is utilized in tumor research to investigate KRAS-mediated signaling pathways and its role in cancer progression. It provides a valuable tool for studying the therapeutic potential of KRAS inhibition in various malignancies. -
Farnesyl Transferase Inhibitor
(Rac)-Tipifarnib is a potent farnesyl protein transferase inhibitor that disrupts the post-translational modification of Ras proteins. By inhibiting farnesylation, it effectively interferes with the activation and function of Ras, leading to significant antitumor effects. This compound is utilized in research focused on cancer therapeutics and the molecular mechanisms underlying Ras-mediated signaling pathways. -
PAT Inhibitor
PAT-IN-2 is a selective inhibitor of protein acyl transferases (PAT), primarily targeting Erf2 autopalmitoylation. By competitively inhibiting this process, PAT-IN-2 serves as a valuable tool for investigating the role of PAT in cellular signaling and lipid metabolism. Its application in research may provide insights into the regulation of protein function via acylation and the development of therapeutic strategies targeting related pathways. -
KRASG12C Inhibitor
KRASG12C IN-18 is a potent covalent inhibitor targeting the KRASG12C mutation. It effectively engages KRASG12C in both GDP- and GMPPNP-bound states, demonstrating significant antiproliferative activity against KRASG12C and its resistance variants, including KRASG12C/R68S, with low nanomolar IC50 values. This compound exhibits substantial in vivo efficacy in models of KRASG12C-driven solid tumors and KRASG12C/R68S xenografts, making it a valuable tool for research in colorectal cancer. -
RAS Inhibitor
RAS-IN-4 is a RAS inhibitor that exhibits significant antitumor activity. This compound interferes with RAS signaling pathways, making it an important tool for researchers studying cancer biology and therapeutic resistance. RAS-IN-4 can be utilized in various in vitro and in vivo studies aimed at understanding the role of RAS in tumor progression and exploring targeted cancer therapies. -
PAT Inhibitor
PAT-IN-1 is a selective inhibitor of protein acyl transferases (PAT), specifically targeting Erf2 autopalmitoylation. It acts through competitive inhibition, thereby altering lipid modifications that influence protein functionality. This compound is valuable for research applications exploring the role of palmitoylation in cellular signaling and protein interactions. -
Cdc42-ITSN Inhibitor
ZCL279 is a small molecule modulator that selectively inhibits the interaction between Cdc42 and intersectin (ITSN). At lower concentrations (<10 μM), ZCL279 stimulates Cdc42 activation, while at higher concentrations, it exerts a significant inhibitory effect on Cdc42 activity. This dual functionality makes ZCL279 a valuable tool for studying the role of Cdc42 in cellular signaling pathways and its implications in various biological processes and diseases. -
Anti-cancer Agent
KRAS G12D inhibitor 13 is a selective inhibitor targeting the KRAS G12D mutation, a critical driver in various cancers. This compound effectively disrupts KRAS-mediated signaling pathways, demonstrating potent anti-cancer activity. It serves as a valuable tool for studying the role of KRAS G12D in tumor biology and evaluating potential therapeutic strategies for KRAS-related malignancies. -
Anti-cancer Agent
KRAS G12D inhibitor 9 is a selective inhibitor targeting the KRAS G12D mutant protein, a crucial element in oncogenic signaling pathways. This compound exhibits significant anti-cancer activity, making it a valuable tool for research focused on KRAS G12D-mediated tumors. Its application is vital for elucidating the mechanisms of KRAS-driven malignancies and developing targeted therapies for patients harboring this mutation. -
KRAS G12C Inhibitor
ZG1077 is a covalent inhibitor targeting the KRAS G12C mutation. It demonstrates potent inhibitory activity against KRAS-driven cancer cell proliferation, making it a valuable tool for studying non-small cell lung cancer (NSCLC) and other KRAS-related malignancies. This compound facilitates research into therapeutic strategies aimed at inhibiting the KRAS signaling pathway. -
K-Ras PM Localization Inhibitor
Oligomycin D, an antibiotic derived from the strain S. rutgersensis, functions as a potent inhibitor of K-Ras plasma membrane localization. By disrupting K-Ras localization, Oligomycin D plays a critical role in cancer research, offering insights into tumorigenesis and potential therapeutic strategies. Its use in various cancer studies provides valuable data for understanding K-Ras-driven malignancies. -
RAS Inhibitor
RAS-IN-5 is a potent RAS inhibitor that effectively disrupts the interaction between RAF1 and active KRAS mutant or wild-type HRAS proteins. This compound demonstrates significant inhibition of cell viability in KRAS, NRAS, and EGFR mutant cell lines. RAS-IN-5 is valuable for research applications focused on colorectal cancer, liver cancer, and non-small cell lung cancer, providing a critical tool for understanding RAS signaling and its role in tumorigenesis. -
KRAS Inhibitor
KRAS inhibitor-11 is a potent inhibitor targeting the KRAS protein, which plays a critical role in cell signaling pathways associated with cancer proliferation. This compound exhibits significant anti-proliferative effects in KRAS-driven tumors, making it a valuable tool for cancer research. It is suitable for studies focusing on KRAS mutations and their implications in oncogenic signaling and therapeutic resistance. -
KRAS G12C Inhibitor
KRAS G12C Inhibitor 26 is a selective inhibitor targeting the mutant form of KRAS G12C. This compound exhibits significant antitumor activity by disrupting downstream signaling pathways associated with cell proliferation and survival. It is primarily utilized in cancer research for evaluating therapeutic strategies against KRAS-driven malignancies and understanding the role of KRAS mutations in tumorigenesis. -
KRAS G12C Inhibitor
KRAS G12C-IN-72 is a selective inhibitor targeting the KRAS G12C mutant protein. This compound exhibits potent activity against KRAS G12C, making it valuable for cancer research, particularly in therapeutic development. It can also serve as a ligand for synthesizing PROTACs, such as KRAS degrader-1, facilitating innovative approaches in targeted protein degradation studies. -
KRas G12D Inhibitor
KRASG12D-IN-4 is a potent inhibitor of the KRAS G12D mutation, exhibiting an IC50 of 3.3 nM. This compound effectively reduces the proliferation of pancreatic cancer ASPC-1 cells, with an IC50 of 12 nM. KRASG12D-IN-4 serves as a valuable tool in cancer research, particularly for studying the therapeutic potential of targeting KRAS mutations in oncology. -
KRAS G12D Inhibitor
KRAS G12D-IN-34 is a potent inhibitor specifically targeting the KRAS G12D mutation, exhibiting IC50 values of 1.05 nM and 1.59 μM for KRAS G12D and wild-type KRAS, respectively. This compound is valuable for research focused on non-small cell lung cancer (NSCLC), providing insights into therapeutic strategies for KRAS-driven tumors. Its selective action enables detailed studies of KRAS-related pathways and potential treatment options. -
KRAS Inhibitor
KRAS inhibitor-32 targets the KRAS protein, a critical component in many oncogenic signaling pathways. This compound exhibits selective inhibition of KRAS, making it a valuable tool for cancer research, particularly in the study of tumor growth and progression in KRAS-driven malignancies. Its application in preclinical studies can aid in understanding the therapeutic potential of KRAS inhibition in various cancer types. -
Anti-cancer Agent
KRAS G12C inhibitor 41 is a selective inhibitor targeting the KRAS G12C mutant protein, a critical player in oncogenic signaling pathways. This compound demonstrates significant anti-cancer activity, making it a valuable tool for investigating KRAS G12C-mediated malignancies. Its application in research can facilitate the development of targeted therapies aimed at overcoming resistance mechanisms in cancer treatment. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 53 is a selective inhibitor targeting the G12C mutated form of the KRAS protein. This compound demonstrates potent anti-proliferative activity in KRAS G12C-driven cancer cell lines, making it a valuable tool in oncology research. It is applicable for studies focused on signaling pathways involved in tumorigenesis and the development of targeted therapies for KRAS G12C mutations. -
KRAS G12C Inhibitor
KRAS G12C Inhibitor 33 selectively targets the KRAS G12C mutant, inhibiting its activity. This compound is essential for investigating the mechanisms of KRAS-driven cancers and contributes to the development of targeted therapies. It is a valuable tool for cancer research, particularly in studies focused on signaling pathways associated with KRAS mutations. -
KRAS Inhibitor
ZINC57632462 (ACA-6) is a non-covalent allosteric inhibitor targeting KRAS. It effectively disrupts nucleotide exchange and impairs RAS-effector interaction, making it a valuable tool for investigating KRAS-related signaling pathways. This compound is particularly relevant for cancer research, enabling studies focused on tumorigenesis and therapeutic interventions. -
K-Ras Inhibitor
(±)-Spiro-oxanthromicin A is a K-Ras inhibitor with an IC50 value of 26.7 μM. This polyketide compound is derived from soil-isolated Streptomyces sp. and has been shown to mislocalize oncogenic mutant K-Ras from the plasma membrane in intact MDCK cells. (±)-Spiro-oxanthromicin A serves as a valuable tool for cancer research, particularly in studies targeting K-Ras-related pathways. -
K-Ras Inhibitor
KS-58 is a K-Ras (G12D) inhibitory peptide that selectively targets and binds to K-Ras. It effectively enters cells to disrupt intracellular interactions between Ras and effector proteins. This compound demonstrates significant antitumor activity by inhibiting the proliferation of tumor cells, making it a valuable tool for research on K-Ras-related cancers and therapeutic interventions. -
KRAS Inhibitor
KRAS-IN-5 is a selective inhibitor targeting KRAS mutants, including KRASG12D and KRASG12V, with a GNE IC50 value of 1.3 nM against KRASG12D. This compound inhibits KRAS-mediated signaling pathways, effectively blocking tumor cell proliferation by reducing ERK phosphorylation. KRAS-IN-5 exhibits potential for research applications in KRAS mutation-related cancers, including pancreatic, colorectal, and lung cancer. -
KRAS G12C inhibitor
KRAS G12C inhibitor 20 is a selective inhibitor targeting the KRAS G12C mutation. This compound exhibits significant anticancer activity by disrupting KRAS signaling pathways, thereby inhibiting cellular proliferation in KRAS-dependent tumors. It is applicable in research focused on cancer biology and targeted therapies for malignancies associated with the KRAS G12C mutation. -
KRAS G12V Inhibitor
KRAS inhibitor-26 is a potent inhibitor targeting the KRAS G12V mutation, exhibiting an IC50 of ≤100 nM. This compound effectively disrupts oncogenic signaling pathways associated with KRAS, making it a valuable tool for cancer research. Its applications include studies on tumor growth, survival, and potential therapeutic interventions in KRAS-driven malignancies. -
Lbc-RhoA Interaction Inhibitor
ZINC09659342 is an inhibitor of the Lbc-RhoA interaction, exhibiting an IC50 value of 3.6 μM. This compound serves as a valuable tool for studying RhoA-mediated cellular processes and signaling pathways. Its ability to disrupt Lbc-RhoA interactions makes it suitable for research applications in cancer biology and cellular mechanism studies. -
KRAS Inhibitor
KRAS Inhibitor-25 is a pyridopyrimidine compound that selectively inhibits KRAS with an IC50 of less than 100 nM for KRas G12V, KRas wild type (WT), and KRas G12R variants. This inhibitor is valuable for research applications focused on understanding KRAS-driven oncogenic signaling pathways and developing targeted cancer therapies. Its potency makes it suitable for studies investigating the biological effects of KRAS mutations and their role in tumorigenesis. -
KRAS-LZTR1 Interaction Modulator
LZTR1-KRAS modulator 1 is designed to modulate the interaction between KRAS and LZTR1, thereby enhancing the recruitment of the LZTR1-KRAS complex. This compound is crucial for studies investigating the regulation of KRAS signaling pathways and their implications in cellular processes. Its application can further elucidate the role of LZTR1 in cancer biology and potential therapeutic interventions targeting KRAS-driven tumors. -
Epac Agonist
8-pHPT-2'-O-Me-cAMP is a cAMP analog that acts as an Epac agonist, specifically enhancing the activity of the exchange protein activated by cyclic AMP (Epac). This compound is utilized in cardiac research to explore signaling mechanisms and cellular responses associated with cardiac function and pathophysiology. Its ability to modulate Epac pathways makes it a valuable tool for investigating the roles of cAMP in cardiac health and disease. -
GGTase-I Inhibitor
GGTI-297 is an inhibitor of geranylgeranyl transferase I (GGTase-1), exhibiting IC50 values of 56 nM for GGTase-1 and 203 nM for farnesyl transferase (FTase). This compound specifically inhibits the geranylgeranylation of the protein Rap1A, effectively disrupting its processing while leaving the farnesylated protein H-Ras unaffected. GGTI-297 is valuable for research applications focused on protein prenylation and its implications in cellular signaling pathways. -
KRAS G12C Inhibitor
KRAS G12C Inhibitor 62 is designed to selectively inhibit the KRAS G12C mutant protein. This compound demonstrates potential in the study of KRAS G12C-mediated cancers, offering valuable insights into therapeutic strategies targeting this challenging oncogenic driver. Its application may facilitate research into tumor growth inhibition and the underlying mechanisms of KRAS-related malignancies. -
RasGRP3 Ligand
RasGRP3 ligand 1 is a specific ligand for RasGRP3 with a binding affinity characterized by a Ki of 1.75 nM. This compound effectively induces Ras activation, making it a valuable tool for investigating downstream signaling pathways in cancer research. Its targeted mechanism allows for detailed studies of RasGRP3's role in cellular processes associated with tumorigenesis. -
Z52/Z56 intermediate
Z52/Z56 intermediate is a crucial building block in the synthesis of RAS inhibitors. This compound plays an important role in facilitating research on the modulation of RAS signaling pathways, which are critical in cancer biology. Its use in the development of RAS-targeted therapeutics makes it valuable for studies focused on oncogenic signaling and drug discovery efforts in oncology. -
L-731735 Prodrug
L 731734 is a prodrug of L-731735, designed to inhibit Ras processing in v-ras-transformed cells. This compound plays a critical role in the study of cell signaling and oncogenic processes associated with Ras. Its application in research provides valuable insights into targeted cancer therapies and the manipulation of Ras signaling pathways. -
Farnesyltransferase Inhibitor
L-739749 is a potent farnesyltransferase inhibitor that selectively inhibits the prenylation of Ras proteins. This compound has demonstrated significant efficacy in blocking the hypersensitivity of juvenile myelomonocytic leukaemia (JMML) cells to granulocyte-macrophage colony-stimulating factor (GM-CSF). In vitro studies show that L-739749 effectively reduces the growth of primary human JMML cells, making it a valuable tool for research into targeted therapies for this disease. -
K-Ras Localization Modulator
(+)-Oxanthromicin is a K-Ras localization modulator that disrupts the localization of oncogenic mutant K-Ras from the plasma membrane in intact Madin-Darby canine kidney (MDCK) cells. This compound demonstrates significant antitumor efficacy, making it valuable for research into cancer biology and potential therapeutic strategies targeting K-Ras-mediated signaling pathways. Its ability to alter K-Ras localization positions it as a promising candidate in the development of targeted cancer therapies. -
RhoA Inhibitor
Dykellic acid is a potent inhibitor of RhoA, a small GTPase involved in regulating cell migration and cytoskeletal dynamics. This compound demonstrates significant inhibitory effects on the migration and motility of B16 melanoma cells, as well as on the tube formation capacity of human umbilical vein endothelial cells (HUVECs). Dykellic acid holds promise for applications in cancer research, particularly related to metastatic processes and tumor microenvironment interactions. -
K-Ras Ligand
SML-10-70-1 is a K-Ras ligand that covalently modifies the K-Ras G12C mutant protein, providing a targeted approach in cancer research. This compound effectively inhibits the phosphorylation of ERK and Akt, key signaling pathways involved in cell proliferation. In vitro studies demonstrate that SML-10-70-1 significantly reduces the proliferation of cancer cell lines H23, H358, and A549, with IC50 values ranging from 26.6 to 47.6 μM, indicating its potential utility in therapeutic applications against K-Ras-driven malignancies. -
Ligand for Target Protein for PROTAC
pan-KRAS ligand 1 is a potent ligand designed for Target Protein applications within PROTAC technology. It facilitates the development of PROTAC pan-KRAS degrader 4, enabling targeted degradation of KRAS mutants. This compound is instrumental for researchers investigating KRAS-related oncogenic pathways and therapeutic strategies against cancer. -
EPAC Activator
Sp-8-Br-2'-O-Me-cAMPS is a cAMP analog that serves as a potent activator of the exchange protein directly activated by cyclic AMP (EPAC). This compound is valuable for studying the role of EPAC in various biological pathways, particularly those related to metabolism. Its ability to modulate EPAC activity makes it an important tool for investigating signaling mechanisms and their implications in metabolic processes. -
Azathioprine Metabolite
6-T-GDP (6-Thioguanosine 5'-diphosphate) operates as a metabolite of azathioprine, targeted for its role in modulating inflammatory responses. By inhibiting Rac1 activity, 6-T-GDP reduces the transcription of inflammatory factors and decreases the expression of cell adhesion molecules. This action subsequently inhibits leukocyte migration and the onset of tissue inflammation, making it a valuable reagent for research into inflammatory diseases and mechanisms of immune regulation.
